Sign in Subscribe
Health care industry

Scipher Medicine Expands Global Reach with Strategic Alliance in Latin America

Strategic Insights

— 1 min read

Scipher Medicine, a leading precision immunology company, has formed a strategic alliance with Grupo Amarey, a leading company in the representation and distribution of technologies, solutions, and services for the healthcare sector in Colombia, Panama, and Costa Rica. This collaboration marks Scipher Medicine's first international expansion, bringing personalized medicine solutions to patients with rheumatoid arthritis (RA) in Latin America, starting with Colombia.

Key Takeaways:

  • Scipher Medicine and Grupo Amarey have formed a strategic alliance to expand the global reach of Scipher Medicine's innovative precision diagnostic, PrismRA.
  • PrismRA is the first molecular test of its kind that provides objective data to help healthcare professionals select the most effective biologic therapy for each RA patient, improving clinical outcomes and reducing unnecessary and ineffective treatments.
  • The partnership aims to bring PrismRA to patients with rheumatoid arthritis in Latin America, starting with Colombia, where Grupo Amarey has extensive experience and a strong presence in the healthcare market.
  • Scipher Medicine's mission is to eliminate the trial-and-error approach in the treatment of autoimmune diseases by providing physicians with actionable, data-driven insights.
  • Grupo Amarey's commitment to innovation and its deep understanding of the local healthcare system make it the ideal partner to bring PrismRA to the patients who can benefit most.
  • The terms of the agreement were not disclosed.
  • This alliance highlights Scipher Medicine's commitment to advancing precision medicine globally and Grupo Amarey's leadership in strengthening healthcare services in Latin America.
  • Scipher Medicine has the industry's largest non-oncology clinico-genomic data asset and biobank, along with electronic medical records (EMR) data for more than 3 million rheumatology patients.

Statistics:

  • 20 million patients worldwide are affected by rheumatoid arthritis (RA) (Source: About PrismRA)
  • PrismRA is a revolutionary blood test bringing precision medicine to the treatment of RA.
  • PrismRA analyzes the patient's individual molecular signature, helping to identify those who are unlikely to adequately respond to TNFi therapy, the world's best-selling drug class.
  • Alternative effective therapies can be prescribed, avoiding unnecessary dose escalations or drug cycles.
  • Physicians now have objective data to inform therapeutic decision-making and give patients the best chance to achieve treatment targets and improve clinical outcomes.

Sources:

  • Scipher Medicine and Grupo Amarey strategic alliance

- Businesswire.com: https://www.businesswire.com/news/home/20250616339070/en/

  • About Scipher Medicine

- www.sciphermedicine.com

  • About PrismRA

- PrismRA.com

  • About Grupo Amarey

- www.grupoamarey.com

Read more